Renal sympathetic denervation: Renal function concerns

Hypertension

Volumn 58, Issue 4, 2011, Pages

  Petidis, Konstantinos ^a   Anyfanti, Panagiota ^a   Doumas, Michael ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN;

ADD ON THERAPY; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; CLINICAL TRIAL (TOPIC); FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY FUNCTION; LETTER; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RENAL SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION;

BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SYMPATHECTOMY;

EID: 80053574353     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.178145     Document Type: Letter

References (4)

1. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
2. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195-1201.
3. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, for the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
4. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16: 925-930. (Pubitemid 37315491)